For­eign threats to NIH re­search: Sen­ate Fi­nance Com­mit­tee digs in

Chi­na, Rus­sia and Iran were sin­gled out in a Sen­ate Fi­nance Com­mit­tee hear­ing on Wednes­day as coun­tries that are look­ing to ei­ther un­der­mine or usurp sci­en­tif­ic re­search con­duct­ed with US tax­pay­er funds.

Chuck Grass­ley Twit­ter

Com­mit­tee Chair­man Chuck Grass­ley (R-IA) made clear that Chi­na is “by far the most pro­lif­ic of­fend­er,” of­fer­ing the ex­am­ple of at­tempts by Chi­nese re­searchers to steal ge­net­i­cal­ly mod­i­fied corn seeds in Iowa and send them back to Chi­na.

“Re­searchers who are se­cret­ly sup­port­ed by a for­eign gov­ern­ment while work­ing on US re­search projects can be more sus­cep­ti­ble to the in­flu­ence and con­trol of the for­eign par­ent. We must know who is fi­nan­cial­ly sup­port­ing re­searchers to bet­ter un­der­stand whether they might be more ded­i­cat­ed to se­cur­ing the in­ter­ests of an ad­ver­sary than to rig­or­ous sci­en­tif­ic and med­ical ad­vance­ment,” Grass­ley said.

As part of ef­forts to com­bat such abus­es, Sen. John Cornyn (R-TX) said he will in­tro­duce a bill next week, called “Se­cure Our Re­search Act,” which would es­tab­lish an in­ter­a­gency work­ing group to set up a com­pli­ance frame­work to pro­tect fed­er­al­ly fund­ed re­search from for­eign in­ter­fer­ence, es­pi­onage and ex­fil­tra­tion.

Michael Schmoy­er HHS

Capt. Michael Schmoy­er, di­rec­tor of the Of­fice of Na­tion­al Se­cu­ri­ty (ONS) at the De­part­ment of Health and Hu­man Ser­vices (HHS), ex­plained the ex­tent of the prob­lem to the com­mit­tee. Since the spring of 2017, ONS be­came “acute­ly aware of spe­cif­ic chal­lenges re­lat­ing to the threat of for­eign in­flu­ences on HHS, and specif­i­cal­ly NIH, re­search in­tegri­ty. We be­came in­volved in two whole-of-gov­ern­ment work­ing groups, led by the FBI, to ad­dress the chal­lenges since some for­eign gov­ern­ments have ini­ti­at­ed sys­tem­at­ic pro­grams to un­du­ly in­flu­ence and cap­i­tal­ize on U.S.–con­duct­ed re­search, in­clud­ing that fund­ed by NIH.”

More specif­i­cal­ly, Louis Ro­di, deputy as­sis­tant di­rec­tor of home­land se­cu­ri­ty in­ves­ti­ga­tions in the De­part­ment of Home­land Se­cu­ri­ty, point­ed to Chi­na, Iran and Rus­sia as be­ing in­volved in the largest num­ber of on­go­ing in­ves­ti­ga­tions re­lat­ed to ei­ther the trans­mis­sion of tech­ni­cal da­ta from the US or the trans­fer of for­eign na­tion­als to the US.

Louis Ro­di LinkedIn

“As of May 2019, there are 357,863 F-1 [visa] Chi­nese stu­dents in the Unit­ed States with 181,980 such stu­dents en­rolled in STEM-re­lat­ed aca­d­e­m­ic pro­grams at U.S. in­sti­tu­tions. There are al­so 11,323 F-1 Iran­ian stu­dents and 6,196 F-1 Russ­ian stu­dents, with the re­spec­tive STEM stu­dent break­down of 9,057 for Iran and 2,008 for Rus­sia,” Ro­di wrote in writ­ten tes­ti­mo­ny.

He of­fered the hy­po­thet­i­cal ex­am­ple of an Iran­ian stu­dent com­ing to the US to study civ­il en­gi­neer­ing, but in re­al­i­ty that stu­dent might be work­ing to study con­crete to aid the Iran­ian nu­clear pro­gram. “So that would be a con­cern to us, us­ing our tech to build these bunkers,” he said. He al­so of­fered the ex­am­ple of an Iran­ian stu­dent com­ing to the US to learn how to weld ti­ta­ni­um for ag­ing Iran­ian air­planes.

Les Hol­lie NIH

Les Hol­lie, chief of in­ves­tiga­tive op­er­a­tions at HHS’ Of­fice of In­spec­tor Gen­er­al, ex­plained how he’s over­seen 16 al­le­ga­tions of non­com­pli­ance, which dealt with prin­ci­pal in­ves­ti­ga­tors that failed to re­veal con­nec­tions to for­eign gov­ern­ments.

In writ­ten tes­ti­mo­ny, Hol­lie of­fered two ex­am­ples of re­cent­ly re­solved re­search in­tegri­ty in­ves­tiga­tive cas­es: One in­volved a doc­tor who worked in a lab­o­ra­to­ry at Iowa State Uni­ver­si­ty, which re­ceived re­search grants for an ex­per­i­men­tal HIV/AIDS vac­cine. The doc­tor fal­si­fied sci­en­tif­ic da­ta to make it ap­pear an ex­per­i­men­tal HIV/AIDS vac­cine neu­tral­ized, or con­trolled, the HIV/AIDS virus in rab­bits, and he con­t­a­m­i­nat­ed rab­bit blood sam­ples with hu­man an­ti­bod­ies to make it ap­pear the rab­bits pro­duced neu­tral­iz­ing an­ti­bod­ies against the HIV/AIDS virus. The da­ta were used in a grant ap­pli­ca­tion and progress re­ports to NIH. In 2015, the doc­tor was sen­tenced to 57 months in fed­er­al prison and re­quired to pay more than $7 mil­lion in resti­tu­tion.

Lawrence Tabak NIH

The oth­er ex­am­ple was a doc­tor who found­ed two com­pa­nies, Gen­Phar and Vax­i­ma, to per­form re­search and pro­duce vac­cines for dis­eases such as Ebo­la, Mar­burg virus and Dengue virus. The com­pa­nies re­ceived NIH funds for biode­fense re­search and vac­cine de­vel­op­ment, but ac­tu­al­ly used the funds for oth­er pur­pos­es, in­clud­ing the con­struc­tion of a com­mer­cial of­fice build­ing and to pay lob­by­ists and oth­ers who were seek­ing to se­cure more fed­er­al fund­ing on the doc­tor’s be­half. In 2017, the doc­tor was sen­tenced to 70 months in fed­er­al prison and or­dered to pay over $3 mil­lion in resti­tu­tion.

Lawrence Tabak, prin­ci­pal deputy di­rec­tor at NIH, added: “The num­bers are small but the prob­lem is im­por­tant. We’ve been work­ing with 61 in­sti­tu­tions, and that num­ber will un­doubt­ed­ly in­crease.”

But Tabak al­so point­ed out how this is­sue is not al­ways black and white and there are sit­u­a­tions in which “hon­est mis­takes were made by re­search in­ves­ti­ga­tors who were un­aware of the re­quire­ment to dis­close oth­er fund­ing sources (both do­mes­tic and in­ter­na­tion­al) or af­fil­i­a­tions with for­eign en­ti­ties.”

Oth­er sen­a­tors and wit­ness­es al­so not­ed the ad­vance­ments made by for­eign-born sci­en­tists in the US.

Sen. Lamar Alexan­der (R-TN) said in a state­ment: “Sci­en­tists from oth­er coun­tries have played an im­por­tant role in re­search fund­ed by the Unit­ed States gov­ern­ment—since 2000, 33 Amer­i­cans who were born in oth­er coun­tries have won No­bel prizes in chem­istry, med­i­cine and physics. Un­for­tu­nate­ly, at­tempts by for­eign gov­ern­ments to in­flu­ence our fed­er­al­ly fund­ed re­search and steal in­tel­lec­tu­al prop­er­ty from the Unit­ed States threat­ens the in­tegri­ty of sci­en­tif­ic re­search.”

Sen. Steve Daines (R-MT) al­so ex­pressed “re­al con­cerns” with Chi­na steal­ing re­search and com­mer­cial­iz­ing that re­search. “Chi­na is open­ing its phar­ma­ceu­ti­cal mar­ket to bet­ter align with in­ter­na­tion­al stan­dards, but you look at the Made in Chi­na 2025: they don’t want to build an open mar­ket but to build a do­mes­tic mar­ket. Chi­na is grad­u­at­ing eight times more STEM grads than what we pro­duce in the US, and I think we’re un­der­es­ti­mat­ing the com­pet­i­tive threat,” he said.

The com­mit­tee was ex­pect­ed to hold a clas­si­fied brief­ing on the mat­ter Wednes­day af­ter­noon.

First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.


Zachary Brennan

managing editor, RAPS

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.